India · Healthcare Network · Expansion-Stage
Ninti Hospital
Collaborative care improving lives, reaching millions. Need-driven super-specialty healthcare network scaling from operational cardiac centres in Bihar to a flagship 350-bed onco-focused super-specialty hospital in Delhi NCR — ~1,000 beds across 6 facilities by 2029.
Raising INR 219 Cr
~1,000 Beds by 2029
Flagship: Delhi NCR Onco
Collaborative care.
Reaching millions.

Ninti Hospital is building a need-driven, specialty-led healthcare network — anchored in operational single-super-specialty cardiac centres in tier-2/3 Bihar, extending to multi-specialty hospitals in Patna and Lucknow, and culminating in a flagship onco-focused super-specialty hospital in Delhi NCR.

Flagship Investment — Delhi NCR
Project CostINR 219 Crore
Beds350 (Super-Specialty)
FocusOncology · Cardiology · Neuro · Ortho
Promoter's FundINR 0.15 Cr
Long-Term DebtINR 218.85 Cr
Construction30 months · COD Month 31
Y10 Projected RevenueINR 1,334 Cr
Y10 Projected PATINR 394 Cr · 30%
01
Executive Summary
The Opportunity

Ninti Hospital is a healthcare network under construction — combining operational single-super-specialty cardiac centres, multi-specialty hospitals under build-out, and a proposed flagship onco-focused super-specialty hospital in Delhi NCR. The network is designed to address India's acute healthcare infrastructure gap: with bed density at 1.42 per 1,000 vs the WHO benchmark of 3.0, and doctor density at 0.86 vs 1.0.

Ninti's current footprint includes Saharsa Cardiac Care (50 beds, operational, broke even September 2024), Muzaffarpur Cardiac Care (broke even September 2024), and Patna Mother Care (100 beds, infrastructure ready). The expansion roadmap adds Purnea (100 beds, 2026), Patna Multispecialty (200 beds, 2027), Lucknow Multispecialty (200 beds, 2027), and the flagship Delhi NCR Onco-focused Super-Specialty Hospital (350 beds, 2029) — taking network capacity to approximately 1,000 beds.

The Delhi NCR project is the pitch: a INR 219 Crore project positioned to capture the Indian oncology market (projected INR 2.5 trillion by 2027) with Delhi NCR cancer incidence rising 23% by 2026. The financial model projects EBITDA breakeven in Year 3, first positive PAT in Year 4, and 30% PAT margin by Year 10 on INR 1,334 Cr of revenue.

02
Performance Metrics
Value Creation · Financial Trajectory · Strategic Positioning
Value Creation Pathway
Flagship Project
350 Beds
Delhi NCR super-specialty
Capital Ask
INR 219 Cr
Project funding
10-Year Target
~1,000 beds
Hospital network roadmap
Financial Trajectory
10-year
Stabilised growth
Strategic Exit
PE / IPO
Network-scale monetization
10-Year Financial Trajectory
INR CrY1Y2Y3Y4Y5Y7Y10
Revenue1453134686498091,0641,334
Gross Contribution68160243344437596800
Gross Margin47%51%52%53%54%56%60%
EBITDA(33)2587175255387553
EBITDA Margin-23%8%19%27%32%36%41%
PAT(84)(19)49112167268394
PAT Margin-58%-6%10%17%21%25%30%
Ramp Inflection Points
Year 2: EBITDA positive. Year 4: first positive PAT (INR 112 Cr) · 27% EBITDA margin. Year 10: INR 1,334 Cr revenue · 41% EBITDA margin · 30% PAT margin — positioned at the top of the Indian private hospital margin distribution, consistent with onco-focused super-specialty economics.
Strategic Positioning — SWOT
Strengths
  • Management with proven cardiac-centre commissioning track record
  • Senior clinical team with 20+ years of super-specialty experience
  • Patient-centric, compassionate-care brand positioning
  • Founder goodwill enabling easy doctor onboarding
  • Cloud-based HIS for operational efficiency from Day 1
Opportunities
  • Rising NCD incidence (cancer, cardiac, neuro) in India
  • Quality oncology care under-supplied outside Delhi/Mumbai
  • Super-specialty mix is the highest-margin hospital segment
  • Cancer awareness and diagnostic tools driving patient inflow
  • Opportunity to leverage medical tourism agency relationships
Weaknesses
  • Successful operations depend on trained staff / doctor retention
  • Dependency on partner hospital billing cycles (SIS model)
  • Revenue directly impacted by equipment downtimes
  • High equipment + specialist cost must be passed through to patients
Threats
  • Competition from entrenched super-specialty chains in Delhi NCR
  • Government price-capping on consumables
  • Poaching of doctors / staff by larger hospital chains
  • Long lead times for specialised lab/imaging equipment
  • Construction/approval delays affecting commissioning
03
Projects
Delhi NCR Super-Specialty — INR 219 Cr Flagship
Upcoming · 2029 COD
Ninti Hospital
Delhi NCR Super-Specialty
Oncology · Cardiology · Neuro · Ortho
Project CostINR 219 Cr · 350 Beds

Flagship onco-focused super-specialty hospital in Delhi NCR — 350 beds, 30-month construction, COD Month 31. Full oncology suite: surgical, medical, radiation, gynae; BMT; IGRT; PET-CT. 99.93% debt-funded (INR 218.85 Cr @ 6%). Projected Y4 first positive PAT (INR 112 Cr), Y10 revenue INR 1,334 Cr at 41% EBITDA · 30% PAT margin · INR 1,961 Cr closing cash. Cardiac-centre breakeven proof points already validated in Bihar.

Disclaimer · Investment Materials
Confidentiality & Forward-Looking Statements
This document summarises publicly-releasable project information and does not constitute an offer or solicitation of an offer to buy or sell securities. Forward-looking statements involve risks and uncertainties; actual results may differ materially. Past performance is not indicative of future results.

Confidential sponsor, contact, and financial details are available to authorized investors via the gated Bio & Contact and Business Plan materials.